[1]
“How much to invest in glycemic control of a patient with diabetes mellitus type 2? A constant dilemma for the Brazilian Public Health System (SUS)”, Braz. J. Pharm. Sci., vol. 55, p. e17197, Nov. 2019, doi: 10.1590/s2175-97902019000117197.